These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 4232726)

  • 1. [On the formation of H-3-dopa from H-3-tyrosine and determination of the dopa synthesis rate in the fowl and cat adrenal gland under in vivo conditions].
    Hempel K; Männl HF
    Naunyn Schmiedebergs Arch Exp Pathol Pharmakol; 1967; 257(4):391-408. PubMed ID: 4232726
    [No Abstract]   [Full Text] [Related]  

  • 2. The conversion of H3-tyrosine to H3-dopa in the adrenal glands under in vivo conditions.
    Hempel K; Männl HF
    Experientia; 1966 Oct; 22(10):689-90. PubMed ID: 5971927
    [No Abstract]   [Full Text] [Related]  

  • 3. [Progress in the therapy of parkinsonism with L-dopa: inhibition of dopa decarboxylase].
    Nurzia A
    Clin Ter; 1975 Feb; 72(3):289-95. PubMed ID: 1132216
    [No Abstract]   [Full Text] [Related]  

  • 4. Transfer of DOPA from the sympatho-adrenal system to the pancreas, liver and kidney via the blood circulation.
    Andén NE; Grabowska-Andén M; Schwieler J
    Acta Physiol Scand; 1989 May; 136(1):75-9. PubMed ID: 2570506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distribution of DOPA-2- 14 C in relation to DOPA-1- 14 C (carboxyl- 14 C-labelled DOPA) in mice before and after inhibition of DOPA-decarboxylase, studied by whole-body autoradiography.
    Tjälve H; Ullberg S
    Arch Int Pharmacodyn Ther; 1972 Oct; 199(2):376-88. PubMed ID: 4627124
    [No Abstract]   [Full Text] [Related]  

  • 6. Inhibition of tyrosine degradation in vivo by the dopa decarboxylase blocking agent NSD-1034.
    Hempel K; Männl HF
    Experientia; 1968 May; 24(5):429-30. PubMed ID: 5674965
    [No Abstract]   [Full Text] [Related]  

  • 7. Conversion of L-tyrosine to 3,4-dihydroxyphenylalanine by cell-free preparations of brain and sympathetically innervated tissues.
    Nagatsu T; Levitt M; Udenfriend S
    Biochem Biophys Res Commun; 1964; 14():543-9. PubMed ID: 5836553
    [No Abstract]   [Full Text] [Related]  

  • 8. Effects of ethanol on central and peripheral noradrenergic neurons.
    Pohorecky LA
    J Pharmacol Exp Ther; 1974 May; 189(2):380-91. PubMed ID: 4829220
    [No Abstract]   [Full Text] [Related]  

  • 9. Cerebral accumulation and metabolism of C14-dopa after selective inhibition of peripheral decarboxylase.
    Bartholini G; Pletscher A
    J Pharmacol Exp Ther; 1968 May; 161(1):14-20. PubMed ID: 5648492
    [No Abstract]   [Full Text] [Related]  

  • 10. Modification of the cardiovascular effects of L-dopa by decarboxylase inhibitors.
    Watanabe AM; Parks LC; Kopin IJ
    J Clin Invest; 1971 Jun; 50(6):1322-8. PubMed ID: 5578236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in tyrosine hydroxylase and dopa decarboxylase induced by pharmacological agents.
    Dairman W; Christenson JG; Udenfriend S
    Pharmacol Rev; 1972 Jun; 24(2):269-89. PubMed ID: 4404613
    [No Abstract]   [Full Text] [Related]  

  • 12. [Utilization of parenterally introduced C-14 insulin by organs and tissues].
    Kritsman MG; Morenkova SA; Perova NV; Konikova AS
    Dokl Akad Nauk SSSR; 1967 Apr; 173(4):974-7. PubMed ID: 5623099
    [No Abstract]   [Full Text] [Related]  

  • 13. [Utilization by organs and tissues of parenterally administered C14-hyaluronidase].
    Korotkina RN; Mitlina IM
    Biull Eksp Biol Med; 1970 Aug; 70(8):44-6. PubMed ID: 5492871
    [No Abstract]   [Full Text] [Related]  

  • 14. Studies on the mechanism of the L-3,4-dihydroxyphenylalanine-induced decrease in tyrosine hydroxylase activity.
    Dairman W; Udenfriend S
    Mol Pharmacol; 1972 May; 8(3):293-9. PubMed ID: 4402746
    [No Abstract]   [Full Text] [Related]  

  • 15. [Action of a decarboxylase inhibitor on endogenous plasmatic DOPA, in man].
    Geissbuhler F; Constantinidis J; Gaillard JM; des Combes NJ; Tissot R
    Biomedicine; 1974 Jul; 21(7):297-8. PubMed ID: 4433662
    [No Abstract]   [Full Text] [Related]  

  • 16. [Influence of amphetamine, ephedrine and their parahydroxylated derivatives on the fixation and distribution of 3 H tyrosine and 3 H dihydroxyphenyl alanine].
    Rapin JR; Jacquot C; Cohen Y; Valette G
    C R Seances Soc Biol Fil; 1971; 165(7):1576-81. PubMed ID: 4261912
    [No Abstract]   [Full Text] [Related]  

  • 17. Differences in the regulation of tyrosine hydroxylase and dopa decarboxylase in sympathetic ganglia and adrenals.
    Black IB; Hendry I; Iversen LL
    Nat New Biol; 1971 May; 231(18):27-9. PubMed ID: 5282850
    [No Abstract]   [Full Text] [Related]  

  • 18. [Distribution of corticosteroid fractions in canine tissues].
    Fazekas AT
    Endokrinologie; 1971; 57(2):159-65. PubMed ID: 5546123
    [No Abstract]   [Full Text] [Related]  

  • 19. A nonisotopic method for determination of the in vivo activities of tyrosine hydroxylase in the rat adrenal gland.
    Hayashi Y; Miwa S; Lee K; Koshimura K; Kamel A; Hamahata K; Fujiwara M
    Anal Biochem; 1988 Jan; 168(1):176-83. PubMed ID: 2896473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Metabolism analysis and autoradiographic demonstration of atropine, scopolamine (C-14, H3) and of their metabolites in various mammals].
    Werner G
    Strahlentherapie Sonderb; 1968; 67():365-75. PubMed ID: 4976016
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.